Facial transplantation becomes a reality! Over 80 people involved, 92% of patients return to work
Release time:
2024-08-20
The repair and treatment of severe head and facial injuries is a global challenge. The team led by Professor Li Qingfeng, Deputy Director of the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and Chief Physician Zhan Tao has achieved a breakthrough in this field after more than a decade of research. Their related research paper was recently published in the international journal "JAMA Otolaryngology–Head & Neck Surgery."
For severe head and facial injury repair, international practices commonly use allograft face transplantation techniques. This technique involves transplanting a donated face onto the patient's face, but due to immune rejection, the patient must take immunosuppressive drugs for life. Limited by factors such as donor shortage and ethical issues, only 50 cases of allograft face transplantation have been performed globally. The first patient who underwent the procedure developed two types of cancer due to anti-rejection treatment.
Li Qingfeng and Zhan Tao's team combined traditional surgical techniques with regenerative medicine, stem cells, and digital three-dimensional technology. In 2012, they pioneered the full-face prefabrication and transplantation technique using autologous tissue, completing the world's first case of this kind. The technique uses the patient's own tissues for transplantation, reducing transplantation risks. In recent years, the research team has refined and standardized this technique, further verifying its safety, efficacy, and scalability.
“In simple terms, our technique grows a face on the patient's chest and then transplants this new face onto the patient's face," Zhan Tao explained. First, using cell transplantation to promote skin expansion and regeneration, a skin flap forms on the patient’s chest. This tissue is at least eight times the area of the original skin, with sufficient blood supply, easy to shape, and matches the facial color. Then, through 3D printing technology, the patient’s own cartilage tissue is used to construct the nose, lips, and eye slits on the new skin and soft tissue. Finally, the prefabricated "face" is transplanted onto the patient's face.
A new technique must undergo long-term observation and practice to prove its safety, reliability, and scalability. The research team continuously standardized surgical procedures during clinical practice, ingeniously combining advanced technologies such as flap prefabrication, 3D printing, and ICG angiography-assisted monitoring with traditional methods. This broadened the application and effectiveness of autologous tissue in facial repair. The recently published paper not only details the standardized technique but also shows through long-term clinical reviews and evaluations that this groundbreaking technology is proven safe and effective, potentially becoming the main treatment method in this field.
Experts such as the president of the American Association of Facial Plastic and Reconstructive Surgery regard this achievement as a "significant advancement in facial reconstruction," providing patients with naturally shaped repair effects and facial functionality, while avoiding the lifelong immunosuppression and associated risks of allograft transplantation.
Currently, the "Chinese style face transplantation" has successfully completed over 80 cases, with 92% of patients returning to study or work. The "face transplantation" technology developed by Li Qingfeng and Zhan Tao's team provides effective treatment for patients with various facial tissue and organ defects, showcasing "Chinese wisdom" in the field of head and facial reconstruction.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
